Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07511218 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase I Clinical Study of AHB - 171 in Healthy Participants(HP) and Chronic Hepatitis B (CHB) Participants

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoints added 8 → 14 primary endpoints
See other at-risk trials from Ausper Biopharma Co., Ltd.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified
    • Study sites: 1 to 2
    v3
  2. Primary endpoint(s) modified
    • Recruitment opened
    • Start date changed from estimate of Apr 15, 2026 to Apr 13, 2026
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to evaluate the safety, tolerability, immunogenicity and Pharmacokinetics (PK) characteristics of AHB-171 Injection in healthy participants (Part A) and participants with chronic hepatitis B (CHB, Part B), and assess its preliminary efficacy in CHB participants.
Trial Details
NCT Number NCT07511218
Lead Sponsor Ausper Biopharma Co., Ltd.
Conditions
(from sponsor)		 Chronic Hepatitis B Infection
Related terms Hepatitis B, Chronic
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov